Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
- Associated Therapies
- -
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 369
- Registration Number
- NCT02865850
- Locations
- 🇺🇦
Research Site, Zhytomyr, Ukraine
🇺🇸Research Site #1, Chattanooga, Tennessee, United States
🇷🇺Research Site #2, Kemerovo, Russian Federation
Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Andrea L Woodland
- Target Recruit Count
- 50
- Registration Number
- NCT02817555
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 1725
- Registration Number
- NCT02680574
- Locations
- 🇷🇸
Research Site #3, Belgrade, Serbia
🇿🇦Research Site #1, Durban, KwaZulu-Natal, South Africa
🇿🇦Research Site #2, Durban, KwaZulu-Natal, South Africa
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 1751
- Registration Number
- NCT02648347
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
🇿🇦Research Site #1, Durban, KwaZulu-Natal, South Africa
🇿🇦Research Site #2, Durban, KwaZulu-Natal, South Africa
Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Biocad
- Target Recruit Count
- 74
- Registration Number
- NCT02506881
- Locations
- 🇷🇺
City Mariin Hospital, St. Petersburg, Russian Federation
Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Biocad
- Target Recruit Count
- 196
- Registration Number
- NCT02506868
- Locations
- 🇷🇺
NEFROS Ltd, Medical Centre, Krasnodar, Russian Federation
🇷🇺N.I.Pirogov City Clinical Hospital #1, Moscow, Russian Federation
🇷🇺Alyans Biomedical - Ural'skaya gruppa, Izhevsk, Russian Federation
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
- Conditions
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 838
- Registration Number
- NCT02278341
- Locations
- 🇵🇱
Site PL48002, Katowice, Poland
🇭🇷Site HR38509, Zagreb, Grad Zagreb, Croatia
🇭🇷Site HR38505, Karlovac, Croatia
Darbepoetin Alfa MDS Companion Protocol
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 9
- Registration Number
- NCT02175277
- Locations
- 🇧🇪
Research Site, Sint-Niklaas, Belgium
Comparison Among Erythropoietin Stimulating Agents
- Conditions
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 327
- Registration Number
- NCT02049346
- Locations
- 🇶🇦
Fahd Bin Jassem Dialysis Centre, Doha, Qatar
Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
- Conditions
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 257
- Registration Number
- NCT02044653
- Locations
- 🇰🇷
Bundang Seoul National University College of Medicine, Gumi, Korea, Republic of
🇰🇷Gangnam severance hospital, Seoul, Korea, Republic of
🇰🇷Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.